ERDERA Clinical Trial Call – Guidelines for Applicants

1:1
These guidelines explain the eligibility rules, submission process and Expression of Interest requirements for the ERDERA Clinical Trial Call.

This document sets out the aim, eligibility criteria, application process, and application instructions for the ERDERA Clinical Trial Call (ECTC).  It also explains the sections required for the Expression of Interest, including project data, project description, the coordinating investigator and sponsor, partners, budget, notes, declarations, submission and data protection.

Acces this publication

publication

ERDERA clinical trial call

Year of publication

2026

Author

European Rare Diseases Research Alliance (ERDERA)

You might also be interested in

How National Mirror Groups strengthen rare disease research and policy alignment in Europe

By connecting national priorities with European initiatives, NMGs support stronger coordination, knowledge exchange and alignment across the rare disease ecosystem.
Scientist reading a journal article 2026

Longitudinal progression, metrics, age-dependence, and modifiers of ataxia severity in SCA27B: a multicentre study of 219 patients

The multicentre observational study analysed 661 assessments from 219 people with SCA27B to examine disease progression, clinical outcome metrics and demographic or genetic modifiers.
Conference "Advancement of Treatments for Rare Diseases" in Cyprus, June 2026

Cyprus conference connects European research priorities with the path to rare disease treatments

At the “Advancement of Treatments for Rare Diseases” conference in Nicosia, European and national policymakers joined clinicians, researchers, regulators, industry representatives and patient advocates to examine how stronger coordination can translate scientific progress into better prevention, diagnosis, treatment and access to care for people living with rare diseases.
ERDERA clinical trial call

ERDERA Clinical Trial Call – Information webinar recording

ERDERA's

search form